Now showing items 1-6 of 6
Downstream coronary effects of drug-eluting stents.
(Am Heart J, 2011-10)
BACKGROUND: Antiproliferative agents used in drug-eluting stents (DES) attenuate atherosclerosis, yet DES implantation has been linked to endothelial dysfunction. The downstream effects of DES on new lesion formation have ...
Effect of obesity on B-type natriuretic peptide levels in patients with pulmonary arterial hypertension.
(Am J Cardiol, 2012-09-15)
Brain natriuretic peptide (BNP) levels are lower in obese patients with left ventricular failure than in their comparably ill, leaner counterparts. The effect of obesity on BNP in patients with pulmonary arterial hypertension ...
Off-label closure during CLOSURE study.
(J Invasive Cardiol, 2012-11)
BACKGROUND: The role of percutaneous closure of patent foramen ovale (PFO) in patients with cryptogenic stroke or transient ischemic attack remains controversial. Registry data have suggested considerable benefit of closure ...
Pulmonary hypertension and elevated transpulmonary gradient in patients with mitral stenosis.
(J Heart Valve Dis, 2010-11)
BACKGROUND AND AIM OF THE STUDY: Pulmonary hypertension frequently complicates mitral stenosis, with a subset of these patients exhibiting pressures well in excess of their mitral valve hemodynamics. The prevalence of this ...
PINOT NOIR: pulmonic insufficiency improvement with nitric oxide inhalational response.
(J Cardiovasc Magn Reson, 2013-09-04)
BACKGROUND: Tetralogy of Fallot (TOF) repair and pulmonary valvotomy for pulmonary stenosis (PS) lead to progressive pulmonary insufficiency (PI), right ventricular enlargement and dysfunction. This study assessed whether ...
Provoked exercise desaturation in patent foramen ovale and impact of percutaneous closure.
(JACC Cardiovasc Interv, 2012-04)
OBJECTIVES: This study was designed to assess the prevalence of provoked exercise desaturation (PED) in patients with patent foramen ovale (PFO) referred for cardiovascular evaluation and to evaluate the impact of PFO closure. ...